Updates and Developments in Oncology: Radiolabelled monoclonal antibodies in the treatment of metastatic cancer
2007
Radiolabelled Monoclonal Antibodies for Metastatic Cancer Treatment
publication
Evidence: moderate
Author Information
Author(s): David M. Goldenberg
Primary Institution: Garden State Cancer Center
Hypothesis
Can radioimmunotherapy improve treatment outcomes for metastatic cancer?
Conclusion
Radioimmunotherapy shows promise for treating certain solid tumors, especially when using improved pre-targeting methods.
Supporting Evidence
- Radioimmunotherapy has been effective in treating non-Hodgkin lymphoma.
- In colorectal cancer, a specific treatment improved median survival to 68 months.
- Pre-targeting methods have shown improved outcomes in certain cancer types.
Takeaway
This study looks at a special type of cancer treatment that uses antibodies to deliver radiation directly to cancer cells, which might help patients live longer.
Limitations
Many trials involve patients with advanced disease, which may not reflect the best use of radioimmunotherapy.
Want to read the original?
Access the complete publication on the publisher's website